- Home
- BOLD vs NNVC Comparison
BOLD vs NNVC Comparison
Compare BOLD & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- NNVC
- Stock Information
- Founded
- BOLD 2018
- NNVC 2005
- Country
- BOLD United States
- NNVC United States
- Employees
- BOLD N/A
- NNVC N/A
- Industry
- BOLD
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- BOLD
- NNVC Health Care
- Exchange
- BOLD Nasdaq
- NNVC Nasdaq
- Market Cap
- BOLD 24.4M
- NNVC 22.5M
- IPO Year
- BOLD 2024
- NNVC N/A
- Fundamental
- Price
- BOLD $1.15
- NNVC $1.45
- Analyst Decision
- BOLD Buy
- NNVC
- Analyst Count
- BOLD 4
- NNVC 0
- Target Price
- BOLD $4.00
- NNVC N/A
- AVG Volume (30 Days)
- BOLD 79.9K
- NNVC 126.6K
- Earning Date
- BOLD 11-06-2025
- NNVC 11-13-2025
- Dividend Yield
- BOLD N/A
- NNVC N/A
- EPS Growth
- BOLD N/A
- NNVC N/A
- EPS
- BOLD N/A
- NNVC N/A
- Revenue
- BOLD N/A
- NNVC N/A
- Revenue This Year
- BOLD N/A
- NNVC N/A
- Revenue Next Year
- BOLD N/A
- NNVC N/A
- P/E Ratio
- BOLD N/A
- NNVC N/A
- Revenue Growth
- BOLD N/A
- NNVC N/A
- 52 Week Low
- BOLD $1.00
- NNVC $0.94
- 52 Week High
- BOLD $4.72
- NNVC $1.92
- Technical
- Relative Strength Index (RSI)
- BOLD 49.88
- NNVC 48.51
- Support Level
- BOLD $1.13
- NNVC $1.42
- Resistance Level
- BOLD $1.16
- NNVC $1.50
- Average True Range (ATR)
- BOLD 0.04
- NNVC 0.06
- MACD
- BOLD 0.00
- NNVC 0.01
- Stochastic Oscillator
- BOLD 62.50
- NNVC 52.63
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.